CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
Erenumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03773562
NCT03773562Phase 4Completed
CompareCT.gov

Imaging the Migraine Brain Pre- and Post-Erenumab: an MRI Study to Identify Functional and Structural Changes That Correlate With Patient Improvement

Mayo Clinic·interventional·Posted Dec 12, 2018·Updated Jan 9, 2024

In Brief

A Phase 4 clinical trial evaluating Erenumab for Migraine. Completed, enrolled 50 participants across 1 site.

Detailed Summary

Researchers are trying to determine if there is a difference between brain images of subjects that do respond to treatment with erenumab and subjects who do not respond to treatment with erenumab using Magnetic Resonance Imaging (MRI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedDec 12, 2018
Enrollment StartMar 25, 2019
Primary CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 7.6 years ago

Interventions

Erenumabdrug

Erenumab will be used per label instructions.